Lucid Diagnostics Inc. - Common Stock (LUCD)

Competitors to Lucid Diagnostics Inc. - Common Stock (LUCD)

Biocept, Inc.

Biocept offers liquid biopsy tests for various types of cancer, similar to Lucid Diagnostics' focus on non-invasive diagnostic solutions. While both companies vie for market share in the cancer diagnostics space, Biocept has a diversified portfolio of tests, which grants them an advantage in addressing multiple cancer types and attracting a wider client base.

Exact Sciences Corporation 

Exact Sciences Corporation focuses on early detection and prevention of colorectal cancer with its Cologuard test, which offers a non-invasive method for screening. Both Lucid Diagnostics and Exact Sciences operate in the diagnostic testing space, specifically targeting early cancer detection. However, Exact Sciences has a more established product in the market and significant revenue streams, giving them a strong competitive advantage.

Fulgent Genetics, Inc.

Fulgent Genetics provides groundbreaking genetic testing services, including oncology tests that compete with Lucid Diagnostics’ offerings. Both companies target the cancer diagnostic market, but Fulgent's established track record in genetic testing and its ability to rapidly adapt to new cancer types through extensive R&D provide them with a competitive edge.

Guardant Health, Inc. 

Guardant Health specializes in blood-based genomic cancer tests, providing insights into cancer profiling for personalized treatment. This positions them directly against Lucid Diagnostics in the realm of cancer detection and management diagnostics. Guardant Health has a substantial market presence and a wide array of genomic solutions, giving them a competitive edge due to their advanced technology and broad clinical data.

OncoCyte Corporation 

OncoCyte develops and commercializes oncology diagnostics, providing tests that aim to improve cancer detection rates. OncoCyte competes with Lucid Diagnostics by targeting similar markets and offering an array of diagnostic tests. However, Lucid Diagnostics might have an advantage in terms of specific endorsements and clinical collaborations that bolster its credibility in clinical settings.